StockUS listing USRLYBNASDAQHealthcareCapital Destroyer

Rallybio Corp(RLYB) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk37Moderate
75%Data
Strong 6177% profit margin
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 88.03M
Reward Ratingⓘ39 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ37 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RLYB to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Rallybio Corp?

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.

AI Brief Pro

The brief on Rallybio Corp

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Rallybio Corp?

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 88.03M, and a P/E ratio of 3.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Discount reflects uncertainty around future performance.

OpenBook Logo Analysis

Reward: Moderate (39)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta-0.768
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.